Cellectra - Proprietary Smart Devices

INOVIO’s DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using one of INOVIO’s proprietary hand-held CELLECTRA^® smart devices. The CELLECTRA device uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA. INOVIO has employed its CELLECTRA^®2000 smart delivery device for over a decade in more than 40 oncology and infectious disease clinical trials, including those for COVID-19 disease.  For intramuscular delivery, INOVIO uses its CELLECTRA 5PSP in its Phase 3 clinical trial for VGX-3100.  INOVIO is developing its next-generation CELLECTRA 3PSP for intradermal delivery.